drugset / Trial / NCT02349802

Autoinjector Device Assessment Study

NCT02349802

Phase 1 Completed 3052 enrolled AstraZeneca Celerion · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Phase I study to determine the device-related injection failure rate of the single-use, pre-filled autoinjector.

Timeline

Start
2013-02
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 4.5 mg
Subject Exenatide Peptide 9 mg

Indications

No indication recorded.